Search

Displaying results 6811 - 6820 of 10000 in total
  1. Drug

    Anselamimab

    go.drugbank.com/drugs/DB17492
    Investigational

    Synonyms: IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS IMMUNOGLOBULIN LIGHT CHAIN AMYLOID (AL) FIBRILS), CHIMERIC MONOCLONAL ANTIBODY (GAMMA1 HEAVY CHAIN CHIMERIC (1-441) (MUS MUSCULUS VH (IGHV2-3*01 (92.6%)-(IGHD, Immunoglobulin g1, anti-(human amyloid fibril) (human-mus musculus monoclonal cael-101 .gamma.1-chain), disulfide with human-mus musculus monoclonal cael-101 .kappa.-chain, dimer
  2. Drug

    Boceprevir

    go.drugbank.com/drugs/DB08873
    ApprovedWithdrawn

    Boceprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 [synthesis]. … Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: VICTRELIS ® CAPSULAS 200 MG (MOLECULA PROTEGIDA)
  3. Drug

    Degarelix

    go.drugbank.com/drugs/DB06699
    ApprovedInvestigational

    Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008. … Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH.

    Products: FIRMAGON ®80MG, FIRMAGON ® 120MG
  4. Drug

    Simeprevir

    go.drugbank.com/drugs/DB06290
    ApprovedWithdrawn

    or PEG-Interferon/ribavirin combination therapy for genotype 1 or 4. … Simeprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated in patient's with HCV genotype 1 for the treatment of chronic hepatitis C virus (HCV) infection.

    Categories: Heterocyclic Compounds, 3-Ring, Cytochrome P-450 SubstratesProducts: OLYSIO 150 MG KAPSUL ,KAPSUL, 28 ADET
  5. Drug

    Methyl aminolevulinate

    go.drugbank.com/drugs/DB00992
    ApprovedInvestigational

    Methyl aminolevulinate is a prodrug that is metabolised to Protoporphyrin IX (a photosensitizer) used in photodynamic therapy.

    Synonyms: methyl 5-aminolevulinate, methyl δ-aminolevulinateProducts: METVIX® CREMA 160 MG/G, Luxerm 160 mg/g Creme
  6. Drug

    Calcifediol

    go.drugbank.com/drugs/DB00146
    ApprovedInvestigationalNutraceutical

    The major circulating metabolite of vitamin D3 (cholecalciferol). It is produced in the liver and is the best indicator of the body's vitamin D stores.

    Mixtures: HEPATAMINE %8 500 ML(SETLI), HEPATAMINE %8 500 ML(SETSIZ)Categories: Vitamin D and Analogues
  7. Drug

    Propantheline

    go.drugbank.com/drugs/DB00782
    Approved

    A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking.

    Categories: Heterocyclic Compounds, 3-RingProducts: Pro-banthine Tablets 7.5 mg
  8. Drug

    Dolichovespula maculata venom protein

    go.drugbank.com/drugs/DB10958
    Approved

    Dolichovespula maculata venom protein is an extract of Dolichovespula maculata venom. Dolichovespula maculata venom protein is used in allergenic testing.

    Mixtures: Mixed Vespid Venom Protein Multidose 13.0 Ml (3900 Mcg), Hymenoptera Venom Product-mixed Vespid Venom Protein (1650 Mcg)Products: Venomil Inj 10mcg/ml White Faced Hornet, Venomil Inj 100mcg/ml White Faced Hornet
  9. Drug

    Isradipine

    go.drugbank.com/drugs/DB00270
    Approved

    It exhibits greater selectivity towards arterial smooth muscle cells owing to alternative splicing of the alpha-1 subunit of the channel and increased prevalence of inactive channels in smooth muscle cells

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: DYNACIRC SRO 5 MG, OPTASIL ®
  10. Drug

    Binimetinib

    go.drugbank.com/drugs/DB11967
    ApprovedInvestigational

    Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib]. … [A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients

    Categories: Heterocyclic Compounds, 2-Ring, MAP Kinase Kinase 2, antagonists & inhibitorsProducts: MEKTOVI® 15 MG TABLETAS RECUBIERTAS, Mektovı 15 mg Film Kaplı Tablet, 84 ADET